THE FREEDOM TO EXPLORE
Put the power to ask bold questions and participate in research within reach of everyday Americans.
The working archive · 14 November 2026Read the fine print.
Read the fine print.
Then imagine better.
A proposal earns its stars by standing up to questions. Here are the four pillars and ten issues guiding this early working draft.
Exploratory editorial analysis, not adopted legislation.
This is a summary of the supplied working brief, not a verbatim prior-team document. No adoption decision or licensed counsel approval is claimed. Primary sources govern; laws can change.
A Right to Research Act: four pillars
EXPERTS IN YOUR CORNER
Build clear pathways for qualified doctors and scientists to collaborate with informed, willing participants.
BREAK OPEN THE GATES
Open practical routes for independent research, community-led discovery, and transparent scientific progress.
YOUR DATA. YOUR DESTINY.
Put the keys to personal health information in the hands of the people who generate it.
The working matrix
Individual inquiry
Current baseline. An IND sponsor can be an individual; a sponsor-investigator is already recognized. Small or one-person studies are not categorically excluded, but still need applicable oversight.
Question for reform. Explore practical support for individual sponsors without inventing a blanket exemption.
21 CFR 312.3 ↗Investigational boundaries
Current baseline. IND requirements and exemptions turn on the investigation and the applicable conditions. A “research use only” label is not permission for a human study.
Question for reform. Create clear navigational tools and qualified assistance; do not replace the legal analysis.
21 CFR 312.2 ↗Timing and accountability
Current baseline. The usual 30-day IND waiting period absent a clinical hold is existing law; FDA may also authorize an earlier start.
Question for reform. Measure real administrative friction without presenting the existing clock as a new right.
21 CFR 312.40 ↗Consent without surrender
Current baseline. Covered informed consent cannot waive legal rights or release investigators and others from liability for negligence.
Question for reform. Distinguish acknowledged experimental uncertainty from defects, misconduct, and negligence.
21 CFR 50.20 ↗Injury and compensation
Current baseline. Required disclosure about available compensation or treatment for injury is not a guarantee of either.
Question for reform. Explore credible injury support and funding; disclose who bears the risk.
21 CFR 50.25 ↗Proportionate review
Current baseline. Expedited IRB review already exists for eligible minimal-risk categories and certain minor changes. It is not a universal bypass.
Question for reform. Improve access to appropriate review while preserving its independent judgment.
21 CFR 56.110 ↗Independent representation
Current baseline. IRB membership rules already address varied backgrounds and unaffiliated membership.
Question for reform. Ask how participant perspectives can be meaningfully represented without claiming diversity is a new invention.
21 CFR 56.107 ↗Access is not a blank check
Current baseline. Right to Try has specific patient, product, and other eligibility conditions. It does not authorize general access to experimental interventions.
Question for reform. Keep any broader proposal distinct from the existing limited statutory pathway.
21 USC 360bbb-0a ↗Data rights with honest limits
Current baseline. HIPAA access and authorization operate within defined scopes. Pseudonyms and tokens do not themselves deidentify data; properly deidentified information may leave Privacy Rule coverage.
Question for reform. Specify identity custody, permitted uses, and realistic withdrawal limits before any data collection.
HHS de-identification guidance ↗Distributed research, accountable results
Current baseline. FDA’s September 2024 decentralized-trial guidance addresses activities outside traditional sites. Applicable registration and results duties remain relevant.
Question for reform. Design local participation with sponsor oversight, safety follow-up, and transparent reporting.
FDA DCT guidance (2024) ↗Reporting is part of responsibility.
For applicable clinical trials, registration and results obligations are addressed in 42 CFR Part 11. A distributed study design does not make accountability disappear.
A legal-team reflection
Good reform should make the duties legible: who is responsible, who can pause the work, and who helps a participant when something goes wrong? A consent checkbox cannot answer those questions on its own.
This reflection is AI-authored and is not a lawyer’s opinion or a representation of licensed legal review.
This initiative is not an approved clinical study. It is not a substitute for an IND, IRB review, professional care, or other applicable requirements. No peptide use or dosing is promoted.